ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Recruiting

Phase 2

ORKA-001ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Sponsor:

Oruka Therapeutics, Inc.

Code:

NCT07090330

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ORKA-001 Induction Dose

Placebo

ORKA-001 Maintenance Dose

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-20. This information was provided to ClinicalTrials.gov by Oruka Therapeutics, Inc. on 2025-11-03.